Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464061 | 0.84 | MEN1 (0.41) | SLC6A9MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3408775 | 0.76 | ALOX5 (0.41) | IGF1RAOC3MEN1KMT2AALOX5 | |
| SCHEMBL3408769 | 0.76 | ALOX5 (0.41) | IGF1RAOC3MEN1KMT2AALOX5 | |
| SCHEMBL3408772 | 0.76 | ALOX5 (0.41) | IGF1RAOC3MEN1KMT2AALOX5 | |
| SCHEMBL1464039 | 0.75 | IGF1R (0.36) | IGF1RAOC3SLC6A9MEN1KMT2A | |
| SCHEMBL1464036 | 0.70 | ALOX5 (0.36) | IGF1RAOC3MEN1KMT2AALOX5 | |
| SCHEMBL12746389 | 0.70 | ALOX5 (0.36) | IGF1RAOC3MEN1KMT2AALOX5 | |
| SCHEMBL16243708 | 0.68 | HDAC3 (0.37) | ALOX5CYP2C9 | |
| SCHEMBL1529441 | 0.68 | RIPK1 (0.53) | AOC3MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5069200 | 0.68 | RIPK1 (0.53) | AOC3MEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | IGF1R 378/4885AOC3 1966/4885SLC6A9 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.